EP3863624A4 - Intermédiaires de cycle de tca et leur procédé d'utilisation - Google Patents

Intermédiaires de cycle de tca et leur procédé d'utilisation Download PDF

Info

Publication number
EP3863624A4
EP3863624A4 EP19870717.6A EP19870717A EP3863624A4 EP 3863624 A4 EP3863624 A4 EP 3863624A4 EP 19870717 A EP19870717 A EP 19870717A EP 3863624 A4 EP3863624 A4 EP 3863624A4
Authority
EP
European Patent Office
Prior art keywords
methods
tca cycle
cycle intermediates
intermediates
tca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19870717.6A
Other languages
German (de)
English (en)
Other versions
EP3863624A1 (fr
Inventor
Andrew D. Levin
David-alexandre GROS
Jai Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imbria Pharmaceuticals Inc
Original Assignee
Imbria Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imbria Pharmaceuticals Inc filed Critical Imbria Pharmaceuticals Inc
Publication of EP3863624A1 publication Critical patent/EP3863624A1/fr
Publication of EP3863624A4 publication Critical patent/EP3863624A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pediatric Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19870717.6A 2018-10-11 2019-10-10 Intermédiaires de cycle de tca et leur procédé d'utilisation Withdrawn EP3863624A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862744251P 2018-10-11 2018-10-11
US201862771289P 2018-11-26 2018-11-26
US201962799064P 2019-01-31 2019-01-31
US201962900921P 2019-09-16 2019-09-16
PCT/US2019/055643 WO2020077094A1 (fr) 2018-10-11 2019-10-10 Intermédiaires de cycle de tca et leur procédé d'utilisation

Publications (2)

Publication Number Publication Date
EP3863624A1 EP3863624A1 (fr) 2021-08-18
EP3863624A4 true EP3863624A4 (fr) 2022-08-31

Family

ID=70165148

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19870717.6A Withdrawn EP3863624A4 (fr) 2018-10-11 2019-10-10 Intermédiaires de cycle de tca et leur procédé d'utilisation

Country Status (9)

Country Link
US (1) US20210346329A1 (fr)
EP (1) EP3863624A4 (fr)
JP (1) JP2022504584A (fr)
KR (1) KR20210076040A (fr)
CN (1) CN112888436A (fr)
AU (1) AU2019359375A1 (fr)
CA (1) CA3113071A1 (fr)
IL (1) IL282147A (fr)
WO (1) WO2020077094A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173546A1 (en) * 2001-02-14 2002-11-21 Matthias Rath Composition of biochemical compounds involved in bioenergy metabolism of cells and method of use
WO2004062658A1 (fr) * 2003-01-09 2004-07-29 Penam Investments Pty Ltd Methode de traitement ou de prevention de symptomes d'une infection par le virus de l'herpes
US20140243400A1 (en) * 2013-02-28 2014-08-28 University of Alaska Anchorage Compositions comprising citric acid and malic acid and methods and uses thereof
WO2015155231A1 (fr) * 2014-04-08 2015-10-15 Neurovive Pharmaceutical Ab Nouveaux composés de succinate perméables à travers les cellules
US20180070614A1 (en) * 2016-09-15 2018-03-15 Givaudan, S.A. Flavored beverages
WO2019023231A1 (fr) * 2017-07-24 2019-01-31 Carnot, Llc Compositions et méthodes pour le traitement d'états associés à un métabolisme de cycle de tca modifié

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537969B1 (en) * 1997-10-24 2003-03-25 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
CA2362016A1 (fr) * 1999-03-03 2000-09-08 Kenneth Philip Moder Complexes d'echinocandine/glucide
CN105963244A (zh) * 2016-01-15 2016-09-28 赵鸣 注射用青蒿琥酯制剂及其应用
US10786476B2 (en) * 2016-02-23 2020-09-29 Imbria Pharmaceuticals, Inc. Combination therapy
WO2017184583A1 (fr) * 2016-04-19 2017-10-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Agents anaplérotiques pour le traitement de troubles associés au métabolisme du propionate et des graisses à longue chaîne
CA3113290A1 (fr) * 2018-10-11 2020-04-16 Imbria Pharmaceuticals, Inc. Compositions et procedes de traitement et de prevention de la neuropathie optique hereditaire de leber

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173546A1 (en) * 2001-02-14 2002-11-21 Matthias Rath Composition of biochemical compounds involved in bioenergy metabolism of cells and method of use
WO2004062658A1 (fr) * 2003-01-09 2004-07-29 Penam Investments Pty Ltd Methode de traitement ou de prevention de symptomes d'une infection par le virus de l'herpes
US20140243400A1 (en) * 2013-02-28 2014-08-28 University of Alaska Anchorage Compositions comprising citric acid and malic acid and methods and uses thereof
WO2015155231A1 (fr) * 2014-04-08 2015-10-15 Neurovive Pharmaceutical Ab Nouveaux composés de succinate perméables à travers les cellules
US20180070614A1 (en) * 2016-09-15 2018-03-15 Givaudan, S.A. Flavored beverages
WO2019023231A1 (fr) * 2017-07-24 2019-01-31 Carnot, Llc Compositions et méthodes pour le traitement d'états associés à un métabolisme de cycle de tca modifié

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LONGO NICOLA ET AL: "Anaplerotic therapy in propionic acidemia", MOLECULAR GENETICS AND METABOLISM, vol. 122, no. 1-2, 1 September 2017 (2017-09-01), AMSTERDAM, NL, pages 51 - 59, XP055932799, ISSN: 1096-7192, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612888/pdf/nihms893694.pdf> DOI: 10.1016/j.ymgme.2017.07.003 *
See also references of WO2020077094A1 *

Also Published As

Publication number Publication date
IL282147A (en) 2021-05-31
WO2020077094A1 (fr) 2020-04-16
AU2019359375A1 (en) 2021-04-29
JP2022504584A (ja) 2022-01-13
KR20210076040A (ko) 2021-06-23
US20210346329A1 (en) 2021-11-11
EP3863624A1 (fr) 2021-08-18
CA3113071A1 (fr) 2020-04-16
CN112888436A (zh) 2021-06-01
WO2020077094A8 (fr) 2021-04-22

Similar Documents

Publication Publication Date Title
IL276731A (en) Antibodies against CD73 and methods of using them
EP3700527A4 (fr) Inhibiteurs de papd5 et leurs méthodes d&#39;utilisation
IL278821A (en) Anti-SIRPA antibodies and methods of using them
EP3810185A4 (fr) Variants d&#39;interleukine-2 et leurs procédés d&#39;utilisation
EP3852805A4 (fr) Anticorps anti-lilrb2 et leurs méthodes d&#39;utilisation
EP3810617A4 (fr) Inhibiteurs d&#39;ectonucléotidases et leurs procédés d&#39;utilisation
IL270214A (en) Anti-sortilin antibodies and methods of using them
EP3752166A4 (fr) Agents de liaison trialcyne et procédés d&#39;utilisation
EP3886853A4 (fr) Composés diarylhydantoine et leurs procédés d&#39;utilisation
EP3728323A4 (fr) Anticorps anti-fzd et méthodes d&#39;utilisation
IL279648A (en) Anti-SIRP-in-cell 1 antibodies and methods of using them
EP3710430A4 (fr) Inhibiteurs d&#39;acss2 et leurs procédés d&#39;utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d&#39;utilisation
EP3710589A4 (fr) Anticorps anti-c1s et procédés d&#39;utilisation
EP3684819A4 (fr) Anticorps anti-ykl40 et méthodes d&#39;utilisation
EP3866858A4 (fr) Conjugués de polynucléotide immunomodulateur et procédés d&#39;utilisation
EP3846808A4 (fr) Inhibiteurs de papd5 et leurs procédés d&#39;utilisation
IL283884A (en) Antibodies against il-36 and methods of using them
IL280338A (en) Anti-SIGLEC-5 antibodies and methods of using them
IL283782A (en) Analosomes and methods of use
EP3743109A4 (fr) Anticorps anti-mica/b et leurs méthodes d&#39;utilisation
EP3749691A4 (fr) Agents de liaison à angptl8 et leurs méthodes d&#39;utilisation
EP3642231A4 (fr) Anticorps anti-vista et méthodes d&#39;utilisation
EP3765485A4 (fr) Immuno-exosomes et leurs procédés d&#39;utilisation
EP3761989A4 (fr) Imidazodiazépinediones et leurs procédés d&#39;utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210507

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMBRIA PHARMACEUTICALS, INC.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220803

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/00 20060101ALI20220728BHEP

Ipc: C07C 69/704 20060101ALI20220728BHEP

Ipc: C07C 69/40 20060101ALI20220728BHEP

Ipc: A61K 31/194 20060101ALI20220728BHEP

Ipc: A61K 31/225 20060101AFI20220728BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230303